- Home
- CERO vs BREA Comparison
CERO vs BREA Comparison
Compare CERO & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- BREA
- Stock Information
- Founded
- CERO 2017
- BREA 2022
- Country
- CERO United States
- BREA Ireland
- Employees
- CERO N/A
- BREA N/A
- Industry
- CERO
- BREA Services-Misc. Amusement & Recreation
- Sector
- CERO
- BREA Consumer Discretionary
- Exchange
- CERO Nasdaq
- BREA Nasdaq
- Market Cap
- CERO 3.5M
- BREA 13.6M
- IPO Year
- CERO N/A
- BREA 2023
- Fundamental
- Price
- CERO $8.92
- BREA $7.61
- Analyst Decision
- CERO Strong Buy
- BREA
- Analyst Count
- CERO 2
- BREA 0
- Target Price
- CERO $45.00
- BREA N/A
- AVG Volume (30 Days)
- CERO 3.3M
- BREA 18.1K
- Earning Date
- CERO 08-13-2025
- BREA 01-01-0001
- Dividend Yield
- CERO N/A
- BREA N/A
- EPS Growth
- CERO N/A
- BREA N/A
- EPS
- CERO N/A
- BREA N/A
- Revenue
- CERO N/A
- BREA $2,988,009.00
- Revenue This Year
- CERO N/A
- BREA N/A
- Revenue Next Year
- CERO N/A
- BREA N/A
- P/E Ratio
- CERO N/A
- BREA N/A
- Revenue Growth
- CERO N/A
- BREA 151.51
- 52 Week Low
- CERO $6.71
- BREA $5.00
- 52 Week High
- CERO $895.40
- BREA $19.50
- Technical
- Relative Strength Index (RSI)
- CERO 46.26
- BREA 56.86
- Support Level
- CERO $9.10
- BREA $5.90
- Resistance Level
- CERO $9.73
- BREA $7.75
- Average True Range (ATR)
- CERO 2.67
- BREA 0.67
- MACD
- CERO 0.04
- BREA 0.07
- Stochastic Oscillator
- CERO 10.50
- BREA 85.50
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.